MAP Pharmaceuticals, Inc. MAPP today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent, which expires in 2028, results from the Company's discovery that dihydroergotamine can be administered to achieve pharmacokinetic profiles that result in both rapid efficacy and minimal side effects. LEVADEX®, which contains the Company's proprietary formulation of DHE, is an orally inhaled investigational drug for the potential acute treatment of migraine in adults that targets the pharmacokinetic profiles described in this patent.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in